InsidersTradesSigma
Follow the Galderma Group AG share price and the full directors' dealings record of the company, a publicly traded company based in Switzerland. Shares are quoted on the CH market, under the authority of SIX SER. Operating in the Healthcare & Pharma sector, Galderma Group AG has published 69 insider filings. Market capitalisation: €41.3bn. The latest transaction was disclosed on 20 August 2026 (Sale). Every trade is accessible without an account.
69
Insider Decl.
n/a
Thresholds
€27m
13 ops.
Buy Volume
€156m
56 ops.
Sell Volume
28Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,605 of 29,063 companies
50.0
score / 100
Value34
Quality67
FCF yld2.5%
Earn yld1.5%
EV/EBITDA38.8x
ROE11%
Gross mgn69%
Net mgn12%
Debt/EBITDA2.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations69 total
1,101 shares@ CHF 170.420.0005% mcap4.7% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8K00082
3,000 shares@ CHF 168.300.0013% mcap15.7% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8I00078
3,000 shares@ CHF 168.300.0013% mcap13.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8I00086
3,000 shares@ CHF 168.300.0013% mcap2.1% of flowISIN CH1335392721SIX:T1Q8I00086
●
Anonymous (an executive member of the board of directors / member of senior management)
18,000 shares@ CHF 180.000.0079% mcap12.9% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8600033
475 shares@ CHF 173.590.0002% mcap2.2% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q8400038
15,000 shares@ CHF 178.220.0066% mcap100.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q7V00032
●
Anonymous (an executive member of the board of directors / member of senior management)
43,436 shares@ CHF 180.520.019% mcap36.1% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q7V00040
●
Anonymous (an executive member of the board of directors / member of senior management)
15,000 shares@ CHF 161.030.0065% mcap17.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4S00084
15,000 shares@ CHF 161.03330.0065% mcap2.1% of flowISIN CH1335392721SIX:T1Q4S00084
●
Anonymous (an executive member of the board of directors / member of senior management)
20,000 shares@ CHF 161.890.0088% mcap23.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000E6
●
Anonymous (an executive member of the board of directors / member of senior management)
25,000 shares@ CHF 161.890.011% mcap29.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000F3
20,000 shares@ CHF 161.88690.0088% mcap2.8% of flowISIN CH1335392721SIX:T1Q4R000E6
25,000 shares@ CHF 161.88690.011% mcap3.5% of flowISIN CH1335392721SIX:T1Q4R000F3
●
Anonymous (an executive member of the board of directors / member of senior management)
15,000 shares@ CHF 160.730.0065% mcap17.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O00067
●
Anonymous (an executive member of the board of directors / member of senior management)
10,000 shares@ CHF 162.850.0044% mcap11.9% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O00075
10,000 shares@ CHF 162.85250.0044% mcap1.4% of flowISIN CH1335392721SIX:T1Q4O00075
15,000 shares@ CHF 160.73290.0065% mcap2.1% of flowISIN CH1335392721SIX:T1Q4O00067
15,000 shares@ CHF 148.500.0061% mcap1.9% of flowISIN CH1335392721SIX:T1Q3U00033
15,000 shares@ CHF 149.000.0061% mcap1.9% of flowISIN CH1335392721SIX:T1Q3Q00049
15,000 shares@ CHF 146.000.0060% mcap1.9% of flowISIN CH1335392721SIX:T1Q3P00033
15,000 shares@ CHF 146.100.0060% mcap1.9% of flowISIN CH1335392721SIX:T1Q3P00041
20,000 shares@ CHF 143.55520.0078% mcap2.5% of flowISIN CH1335392721SIX:T1Q3O00077
20,000 shares@ CHF 143.17670.0078% mcap2.5% of flowISIN CH1335392721SIX:T1Q3O00069
500 shares@ CHF 141.54030.0002% mcap0.3% of flowISIN CH1335392721SIX:T1Q3I00087
25 of 69 declarations
关于 Galderma Group AG
高德美集团股份公司（Galderma Group AG）是一家全球皮肤病学专业公司，在瑞士SIX瑞士交易所（SMI/SPI）上市，股票代码为PY3.F。该公司将自己定位为纯粹的皮肤病学领域领导者，拥有涵盖注射美容、皮肤科护肤和治疗性皮肤病学的综合产品组合。高德美成立于1981年，围绕皮肤健康建立了其特许经营权，并已发展成为一个具有广泛国际影响力的优质、科学主导平台。其总部位于瑞士楚格，2025年，该集团还通过在迈阿密设立新的美国总部加强了其运营足迹，突显了美国市场的战略重要性。（[galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai)） 在运营上，高德美围绕三个核心业务线进行组织。在注射美容领域，该公司销售成熟品牌，如神经调节剂中的Dysport/Azzalure和Alluzience，以及透明质酸填充剂和生物刺激剂中的Restylane和Sculptra。在皮肤科护肤领域，Cetaphil是其旗舰消费品牌之一，辅以Alastin。在治疗性皮肤病学领域，高德美解决慢性且具有医学重要性的疾病，包括痤疮、特应性皮炎和结节性痒疹，其较新的资产如Nemluvio正在扩大公司的治疗范围。这种组合为该集团带来了多元化的收入基础，并在医疗和消费渠道中拥有多个增长动力。（[galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai)） 高德美的竞争地位建立在科学信誉、广受认可的品牌组合以及对结构性有吸引力的皮肤病学市场的接触之上。管理层强调其产品线的广度和创新管线的深度是与规模较小、专注度较低的竞争对手相比的关键差异化因素。在地理上，该公司是真正的全球性公司，在北美、欧洲、亚太和国际市场均有商业存在，而美国仍然是主要的盈利和增长引擎。最近的发布和产品线扩展强化了公司的优质化战略及其在医生主导和消费者主导类别中扩大市场份额的能力。（[galderma.com](https://www.galderma.com/our-strategy?utm_source=openai)） 最近的里程碑对股权故事尤为重要。2024年，高德美于3月22日在SIX瑞士交易所完成了首次公开募股，公司称这是自2017年以来瑞士最大的IPO。2024年全年业绩显示出稳健增长，2025年进一步加速，包括创纪录的销售额以及Nemluvio、Relfydess和Sculptra在中国市场的增长势头。这一势头延续到2026年初，当时公司报告了强劲的第一季度销售增长。对于投资者而言，高德美将防御性医疗保健敞口与高于市场的有机增长潜力以及重要的管线催化剂相结合，使其成为值得关注的重要的瑞士上市医疗保健公司。（[galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai)）
